TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product
Endpoint domain: Adverse events/effects
Primary endpoint: PGT121.414.LS maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of POD (Postoperative Delirium)
Endpoint domain: Adverse events/effects
Primary endpoint: Low-Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average change in glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systolic BP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of brain tau deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of [212Pb]VMT-alpha-NET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of [212Pb]VMT-alpha-NET
Endpoint domain: Adverse events/effects
Primary endpoint: ECAP Measurement in Microvolts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall feasibility of Viamigo intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recruitment and drop-out rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peak electrical activity of the diaphragm (Edi peaks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum electrical activity of the diaphragm (Edi mins)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of apenic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bradycardia events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of desaturation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Proportion of 50% responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean patient PROMIS-Preferences
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject Compliance with Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of total adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with successful opening of the blood brain barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve (AUCtau) of ianalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Observed maximum blood concentration (Cmax) of ianalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time of maximum observed drug concentration occurrence (Tmax) of ianalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular ectopy burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The incidence and severity of adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Deep Molecular Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease vaginal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Prolong pregnancy to 36 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Favorable perinatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from valve related death
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from valve related reintervention
Endpoint domain: Mortality/survival
Primary endpoint: Cigarette Demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of H80
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Opioid Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of individuals who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: subjective responses regarding symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of chronic post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: Change in mean hemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breath/blood alcohol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change from baseline in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of completers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of PDMP check encounters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Initiated controlled medication prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total days of Cytomegalovirus (CMV) active antiviral therapy (AVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of participants with treatment emergent serious adverse events (TESAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Credibility and Expectancy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PAP adherence (minutes)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-Care Behavior Assessment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Body Mass via Bioelectrical impedance (BIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PedsQL QoL / DMD QoL - Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modification of mutations in fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stool Antigen Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of NHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of overall wastage of IV drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of drinks consumed during bar-lab paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gamma aminobutyric acid (GABA) and glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of cortical activation to visual cues of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scores of symptoms on the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enteric infections
Endpoint domain: Adverse events/effects
Primary endpoint: Tungiasis infections
Endpoint domain: Adverse events/effects
Primary endpoint: STH infections
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change in Weekly Urticaria Activity Score (UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex regional pain syndrome Severity Score (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline functional status at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline nutritional status at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of men diagnosed with prostate cancer (PC) and aggressive prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rates and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative postoperative 24 h morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of sustained minimal residual disease (MRD) negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change of time spent on 10-minute bout MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving clinical response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in predictors of relapse and recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evacuation duration of rectal balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Appropriateness of diagnostic imaging exams
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hydrogen Peroxide Concentration in Exhaled Breath Condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-isoprostanes Concentration in Exhaled Breath Condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive Protein Concentration in Exhaled Breath Condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine Concentration in Exhaled Breath Condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK] Concentration in Exhaled Breath Condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage in monthly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Complete Hematologic Response (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 28 day all-cause mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of Replication - cost analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Molecular testing pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of reoperation for wound complication or PJI at one year
Endpoint domain: Mortality/survival
Primary endpoint: Change in clonotype diversity of T cell and B cell repertoires
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine Release Syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Delta Nol index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in FEV1 AUC (0-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in morning pre-dose trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spinal Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prior clinical trial participation status
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RBC energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: GMT of VZV antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Manual grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life according to Short- Form 36 Questionnaire (SF - 36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Assessment of exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of local reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious adverse events (SAEs) leading to early participant withdrawal or permanent discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Repetitive Behavior Scale-Revised (RBS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACR/EULAR Total Improvement Score (TIS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters, Vital Signs and ECG Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Overall Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in tic severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants that experience each treatment-emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of acceptability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Log2 of tumor DHFR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean whole body tumor absorbed dose (WB Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median PORTOS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional near-infrared spectroscopy (fNIRS)-measured neural activation and connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Go/no-go task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of loss-of-control eating and purging episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of loss-of-control eating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unplanned hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Oral medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval difference between AED arrival of drones versus law/fire/EMS arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weight at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Weight at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with and types of prenatal features of Lysosomal Storage Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with the presence and levels of glycosaminoglycans (GAGs) in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants that show functional cardiac, growth, mobility, and neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent trichrome or elastic or fiber staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent neutrophils in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent eosinophils in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opioid requirement in morphine equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of grade 3-5 non-hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of ≥ grade 3 CNS toxicities related to non-target embolization
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of symptomatic brain radiation necrosis requiring medical or surgical intervention and confirmed by pathology
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in Alanine Aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in walking and reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural activity during spatial working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Core PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Pain and Functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 Repetition Sit and Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Seroconversion rate against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate against IIV4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate against PPV23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants still receiving treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective Cognitive Workload
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived Cognitive Load
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Genetic Counseling Appointments Completed Following MPM Delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Genetic Counseling Appointments Completed Following Provider Nudge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Simulator Sickness Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Syndecan 1, 2, 3, 4 levels in placenta tissues and amnion membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syndecan 1, 2, 3, 4 levels in maternal and cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in reported physical fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in mental / emotional fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Multi-dimensional Fatigue Inventory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of participants that experience spontaneous syncopal events
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change from baseline in forced vital capacity (FVC) measured in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of dose limiting toxicities (dose escalation phase)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dose limiting toxicities (dose expansion phase)
Endpoint domain: Adverse events/effects
Primary endpoint: Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in PDQ total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enrollment rates to ComboMATCH treatment trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with parenchymal ICH or non-ICH major hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of participants with ischemic stroke, intracerebral hemorrhage or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Safety of pNGVL4aCRTE6E7L2 DNA vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of pNGVL4aCRTE6E7L2 DNA vaccination
Endpoint domain: Resource use
Primary endpoint: Safety of PVX-6 vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of PVX-6 vaccination
Endpoint domain: Resource use
Primary endpoint: Area Under the Concentration versus Time Curve from Time 0 to 24 hours (AUC0-24) of enlicitide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of enlicitide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes